Market Place
Sourcing Support
AIM Immuno Gets US Patent For Ampligen® In Endometriosis Treatment
03 Oct 2024 //
GLOBENEWSWIRE
AIM ImmunoTech To Participate In Virtual Investor CEO Connect
27 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Positive Data In Pancreatic Cancer Study
19 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech: Ampligen Shows Promise For Post-COVID Fatigue
11 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech`s Ampligen Study For Pancreatic Cancer Published
20 Aug 2024 //
GLOBENEWSWIRE
AIM ImmunoTech To Discuss Q2 2024 Results On August 16
13 Aug 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29 Jul 2024 //
GLOBENEWSWIRE
AIM Reports New Data On Ampligen`s Anti-Tumor Potential In Combo Therapy
24 Jul 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Publication +VE Findings a Study Evaluating Ampligen
25 Mar 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces First Subject Dosed for Phase 1b/2 Evaluating Ampligen
14 Feb 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Positive Results from Phase 2 Study Evaluating Ampligen
08 Feb 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Enrollment in the Phase 1b/2 Evaluating Ampligen
22 Jan 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Open Enrollment for Ph 1b/2 Study Evaluating Ampligen
10 Jan 2024 //
GLOBENEWSWIRE
AIM Immuno Announces Completion of Enrollment in Phase 2 Evaluating Ampligen
08 Aug 2023 //
GLOBENEWSWIRE
AIM Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen
10 Jul 2023 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Publication of +VE Findings from a Pre-Clinical Study
27 Jun 2023 //
GLOBENEWSWIRE
AIM Announces Publication of Analysis of the Mechanism of Action of Ampligen
07 Mar 2023 //
GLOBENEWSWIRE
AIM Announces PII of Ampligen for Pancreatic Cancer
28 Feb 2023 //
GLOBENEWSWIRE
AIM ImmunoTech Broadens Patent Portfolio with Utility Patent Covering Ampligen
09 Jan 2023 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Positive Safety, Tolerability Activity Data for Ampligen
08 Dec 2022 //
GLOBENEWSWIRE
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod)
02 Nov 2022 //
GLOBENEWSWIRE
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen
12 Oct 2022 //
GLOBENEWSWIRE
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen
12 Oct 2022 //
GLOBENEWSWIRE
AIM ImmunoTech & Study Collaborator Roswell Park Enrollment NCI Ph2 Ampligen®
30 Aug 2022 //
GLOBENEWSWIRE
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
15 Aug 2022 //
BUSINESSWIRE
AIM ImmunoTech Bolsters IP Portfolio for Ampligen
13 Jun 2022 //
GLOBENEWSWIRE
AIM ImmunoTech provides Phase III efficacy update on Ampligen for long Covid
19 May 2022 //
CLINICALTRIALSARENA
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial
20 Sep 2021 //
GLOBENEWSWIRE
AIM seeks FDA approval to study Ampligen for Covid-19
09 Sep 2021 //
PHARMACEUTICAL-TECHNOLOGY
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Ampligen
29 Jan 2021 //
GLOBENEWSWIRE
AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
07 Jan 2021 //
CLINICALTRIALSARENA
AIM ImmunoTech to recruit long-term chronic COVID-19 patients in Ampligen trial
06 Oct 2020 //
GLOBENEWSWIRE
AIM ImmunoTech inks pact with Roswell Park to test Ampligen
09 Jul 2020 //
PROACTIVEINVESTOR
AIM ImmunoTech files provisional patent application for Ampligen
11 Jun 2020 //
PROACTIVEINVESTORS
AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial
14 May 2020 //
YAHOO
AIM ImmunoTech Announces FDA for First Human Ampligen Trial in COVID-19
14 May 2020 //
PRESS RELEASE
Hemispherx Biopharma Commencement of Rights Offering Subscription Period
15 Feb 2019 //
GLOBENEWSWIRE
